TY  - BOOK
AU  - Schmidt, Stefan R.
TI  - Fusion protein technologies for biopharmaceuticals : applications and challenges
SN  - 9781118354
AV  - RM301.4 .F87 2013
U1  - 615.7 23
PY  - 2013///
CY  - Hoboken, New Jersey
PB  - John Wiley & Sons
KW  - Biopharmaceutics
KW  - Pharmaceutical biotechnology
KW  - Drug carriers
KW  - Immunotoxins
KW  - Therapeutic use
KW  - Protein engineering
KW  - Recombinant fusion proteins
KW  - MEDICAL
KW  - Pharmacology
KW  - bisacsh
KW  - fast
KW  - Recombinant Fusion Proteins
KW  - therapeutic use
KW  - Drug Carriers
KW  - pharmacokinetics
KW  - Protein Engineering
KW  - Electronic books
KW  - local
N1  - Includes bibliographical references and index; pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm
N2  - The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with EnbrelŽ being one of the best-selling biologics worldwide. EnbrelŽ represents a milestone of modern therapies just as HumulinŽ, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and OrthocloneŽ the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei
UR  - http://onlinelibrary.wiley.com/book/10.1002/9781118354599
ER  -